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ABSTRACT Postnatal rat retinal ganglion cells (RGCs)
were identified with specific fluorescent labels and placed in
culture. Under these conditions, the outgrowth of processes by
RGCs was found to be promoted to a far greater degree by
acidic fibroblast growth factor (aFGF) than by basic fibroblast
growth factor (bFGF). The effect of aFGF and bFGF on
process extension by solitary RGCs was quantified after 24 hr
in culture, a time when neither aFGF nor bFGF enhanced
RGC survival. The action of aFGF on process outgrowth was
markedly potentiated by the addition of heparin (10 ,ug/ml) to
the medium, but heparin alone had no effect. In the presence
of heparin, half-maximal process outgrowth occurred at an
aFGF concentration of <20 pg/ml (1 pM). Since all of the
centrally projecting processes have already been formed in the
living animal prior to use (at 7-12 days of age), at least a
portion of the process outgrowth in culture appears to repre-
sent a regenerative phenomenon. Statistical analysis of the
increase in process growth revealed that aFGF with heparin
contributed to both neurite initiation and elongation. The
mean number of glial cells, identified with polyclonal antise-
rum against glial fibrillary acidic protein, was slightly in-
creased in cultures receiving aFGF plus heparin, but this ef-
fect was variable, and these glial cells were not in contact with
the solitary RGCs that were scored for regeneration of pro-
cesses. Thus, glial cells probably did not exert a direct physical
influence on the degree of process outgrowth observed in the
solitary RGCs, although a humoral effect cannot be totally
excluded. These results suggest that aFGF has a potent
influence on the outgrowth of processes by a neuron in the
mammalian central nervous system. The potentiation of this
effect by heparin leads us to speculate that the interaction of
aFGF with a heparin-like molecule located in the extracellular
matrix (such as heparan sulfate proteoglycan) may produce
physiological effects in vivo. Furthermore, the lack of a
substantial effect of bFGF in this system under these condi-
tions shows that a specific population of mammalian central
neurons may be differentially influenced by these two closely
related peptide growth factors.
A variety of growth factors appear to be important for the
extension of processes or neurites in the mammalian nervous
system. Nerve growth factor (1) is the prototype of these
neurotrophic substances, but others have been characterized
(2-4). Among the substances with possible neurotrophic
activity in the central nervous system (CNS) are acidic and
basic fibroblast growth factors, which represent distinct but
homologous gene products (5, 6). Both have been shown to
be potent mitogens for a variety of cell types, including
endothelial cells, astrocytes, and fibroblasts (7-10). Many of
the effects of acidic fibroblast growth factor (aFGF) are
potentiated by heparin-like molecules to a far greater degree
than the actions of basic fibroblast growth factor (bFGF) (11,
12). It has been shown that in PC12 cells aFGF and bFGF
induce neurite outgrowth (11, 13). In addition, purified
bFGF substantially promotes both cell survival and process
extension in primary cultures of fetal rat hippocampal and
cortical neurons (12, 14). In contrast, highly purified aFGF
increases survival of hippocampal neurons somewhat less
effectively than bFGF and exhibits only very minimal effects
on process outgrowth (15).
aFGF has been isolated from bovine hypothalamus, ret-
ina, and other CNS areas; a small amount has also been
found in bone (16). In contrast, bFGF has been encountered
in virtually every tissue examined to date (17). Since both
aFGF and bFGF are present in the adult CNS, the question
naturally arises as to whether or not these potential neuro-
trophic factors are capable of influencing not only initial
neurite outgrowth but also the regrowth of processes from
injured CNS neurons. Since we originally purified aFGF
from retina (10), we wanted to observe its effects on an
appropriate central neuron, the retinal ganglion cell (RGC).
If aFGF could stimulate the regeneration of processes by a
postnatal, differentiated neuron from the mammalian CNS,
it could be of clinical benefit. In this report, we demonstrate
that aFGF, to a far greater degree than bFGF, enhances the
growth of processes by cultured rat RGCs obtained from 7-
to 12-day-old animals. Since by this age all of the centrally
projecting processes of the RGCs have been fully formed
(for references see ref. 18), at least some of this growth
represents regeneration of neurites. The finding that bFGF
did not result in a substantial increase in neurite outgrowth
by RGCs suggests that aFGF and bFGF may work on
separate populations of central neurons and that their effects
might be mediated, at least in part, through distinct recep-
tors.
MATERIALS AND METHODS
Fibroblast Growth Factors. aFGF and bFGF were purified
from bovine retinas or brains by taking advantage of their
affinity for heparin (10). Purification of aFGF to homogene-
ity was as described by Gospodarowicz et al. (19), yielding
two biologically active forms (11, 21). bFGF was purified by
the method of Lobb and Fett (20). Immunoblot analysis with
monospecific antisera raised against synthetic peptides (22)
was used to demonstrate that the aFGF and bFGF used in
these studies were homogeneous and free from cross-
contamination. One unit of activity of the fibroblast growth
Abbreviations: aFGF and bFGF, acidic and basic fibroblast growth
factors; GFAP, glial fibrillary acidic protein; RGC, retinal ganglion
cell; CNS, central nervous system.
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factors is defined as the concentration required to obtain
half-maximal incorporation of [3H]thymidine by 3T3 cells
(10) and is equivalent to -0.2 ng of the purified protein for
aFGF and 0.05 ng for bFGF. To show that the preparations
of growth factor used in these experiments were active, each
batch of highly purified aFGF and bFGF was tested on 3T3
cells both before and after their use in RGC cultures.
Retinal Culture Methods. Retinas of Long Evans rat pups
(age 7-12 days) were dissociated and cultured on glass
coverslips as described (18). RGCs were identified with
fluorescent dyes (18).
Quantification of RGC Survival and Regeneration of Pro-
cesses. After 24 hr in culture, the RGCs were scored for
survival and process outgrowth by the methods developed in
this laboratory (18), with slight modifications. The survival
of both solitary and clustered RGCs was assessed under
phase-contrast optics by their bright appearance, the ability
to accumulate fluorescein from fluorescein diacetate, and
the presence of normal electrical activity (18, 23, 24). Retinal
cultures were fixed with 4% (wt/vol) paraformaldehyde in
0.1 M sodium phosphate buffer. Process outgrowth by
solitary RGCs was analyzed with phase-contrast microscopy
by using a drawing tube to digitally encode the lengths with
a bitpad and puck (Summagraphics) tied to a VAX 11/780
computer (Digital Equipment, Maynard, MA). Clustered
RGCs could not be analyzed in this manner because many of
their processes were hidden among the clumps of other
retinal cells. It was necessary to quantify processes while
visualizing them under the microscope and not from photo-
graphs because many small processes were often in a differ-
ent focal plane from the cell body and could be easily
overlooked if the focal length and ambient light were not
continually varied.
RESULTS
Lack of Effect ofaFGF and bFGF on RGC Survival After 24
hr in Culture. Compared with sibling postnatal cultures, the
survival of RGCs after 1 day in culture did not appear to
differ in medium alone or in medium containing bFGF or
aFGF (even with the addition of heparin) (Fig. 1). This
finding held true for both solitary and clustered RGCs.
Survival at 24 hr was assessed since this time was chosen to
quantify process outgrowth in previous studies (12).
aFGF Is Associated with Substantially More Process Out-
growth by RGCs than bFGF. After 1 day in culture, the
solitary RGCs were scored for process regeneration. Fig. 2
presents photographs of representative RGCs grown in
control medium and in medium containing 10 units/ml aFGF
with heparin (10 4g/ml). On average a greater fraction of
RGCs cultured in the presence of aFGF plus heparin grew
neuronal processes, and the total length of processes per
RGC was longer than in control medium. On the other hand,
under these conditions treatment with bFGF did not sub-
stantially affect process outgrowth. Fig. 3a shows a dose-
response curve for bFGF and for aFGF in the presence and
absence of heparin (10 ,ug/ml). The control contained no
added bFGF, aFGF, or heparin. In the absence of aFGF
=30% of the solitary RGCs regenerated at least one process
longer than the diameter of the cell body, similar to reported
control findings (18). There was a graded increase in the
proportion of RGCs with processes as aFGF was increased
from 0.1 to 10 units/ml. At a larger dose (100 units/ml) this
proportion began to decrease back toward the baseline,
suggesting an inhibitory effect of higher concentrations of
aFGF. Heparin enhanced the effects of aFGF at all concen-
trations by further increasing the percentage of ganglion cells
that grew processes, but heparin alone had no effect. In
addition, the total length of processes per solitary RGC
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FIG. 1. Survival after 24 hr in culture of solitary (a) and
clustered (b) RGCs grown on glass coverslips under control condi-
tions, in the presence of aFGF (10-100 units/ml) plus heparin (10
sg/ml), or in bFGF (10-20 units/ml). Values are mean ± SEM of
quadruplicate samples from three separate experiments. The num-
ber of RGCs represents the pooled data from the four coverslips for
each experiment.
FIG. 2. Process outgrowth in 24-hr cultures of RGCs cultured on
glass coverslips in aFGF (10 units/ml) plus heparin (10 ,ug/ml) (b) or
in control conditions (a). The RGCs were labeled prior to dissocia-
tion by retrograde transport of the fluorescent dye granular blue
(18). In b straight arrows mark the major cell process that extends
out of the field, and curved arrows point to the growth cones of
branches or smaller processes. Photographed with a combination of
epifluorescence and phase-contrast microscopy. (Bar = 10 ,um.)
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FIG. 3. Determination of aFGF concentration necessary for
process outgrowth in the presence and absence of heparin (10
,ug/ml). (a) Percentage of solitary RGCs that grew at least one
process as long as the cell body is plotted versus the dose of aFGF
(in units/ml) ± heparin, or bFGF (in units/ml) ± heparin. (b) Total
length of processes per RGC is plotted versus the dose of aFGF (in
units/ml) ± heparin, or bFGF (in units/ml) ± heparin. Data are
shown for one of five experiments with similar results for aFGF.
One of several experiments with bFGF is illustrated in which aFGF
was also tested. Each experiment was based on quadruplicate
platings of retinal cells. Values are means ± SEM; control cultures
did not receive aFGF, bFGF, or heparin. The data for the percent-
age of RGCs growing processes (as in a) were analyzed with an
extension of Fisher's exact test as described in ref. 18; the values for
all concentrations illustrated of aFGF plus heparin were signifi-
cantly greater than the control (P < 0.0001 after Bonferroni's
correction). The results with heparin alone (10 ,ug/ml) or bFGF were
not statistically different from the controls. Heparin (10 /ug/ml) did
not substantially enhance the effect of bFGF.
appeared to be significantly increased with increasing doses
of aFGF up to 10 units/ml (Fig. 3b). At a dose of 100
units/ml, aFGF again appeared to be somewhat inhibitory
compared with 10 units/ml. Heparin (10 ,ug/ml) potentiated
the ability of aFGF to increase the length of processes per
cell. When aFGF was inactivated by prolonged storage, it
was no longer effective; the results were no different from
the controls. In experiments in which aFGF stimulated
neurite outgrowth, bFGF at 0.1, 1.0, 10, or 20 units/ml did
not substantially enhance process outgrowth in sibling cul-
tures in the presence or absence of heparin (Fig. 3).
aFGF Increases Neurite Initiation and Elongation. The fact
that process outgrowth was enhanced by aFGF and heparin
suggested that in the presence of aFGF the RGCs produced
more processes, increased the elongation of existing pro-
cesses, or did both. If the RGCs regenerated more processes
in aFGF than did the control cells, then this finding would
imply that the neurotrophic factor was in some way respon-
sible for the initiation of growth of additional processes. If
neurites were longer in the presence of aFGF than neurites
in control cells, then aFGF might modulate the elongation of
processes. In fact, the number of processes per RGC and the
length of each process increased in cultures treated with
aFGF plus heparin (Table 1 and Fig. 4).
Table 1 shows that RGCs cultured in aFGF plus heparin
regenerated more processes per cell than RGCs in control
medium. Since nothing is known of the form of the population
of the number of processes per cell, it cannot be assumed to
be normally distributed; thus, the data were analyzed with a
nonparametric test. Even though such tests are less powerful
than parametric statistics, the results were highly significant
and showed that, in the presence of aFGF and heparin, RGCs
produced more processes per cell than controls.
To use normal statistics to compare the length of each
process in control medium and aFGF-containing medium, the
lengths of processes would have to be normally distributed.
Unfortunately, this was not the case; Fig. 4 a and b shows that
a graph of the number of neuronal processes versus their
individual lengths reveals a population skewed toward shorter
process lengths. Nevertheless, a simple mathematical trans-
formation of the data (taking the natural logarithm of the
process lengths) resulted in a normal distribution (Fig. 4 c and
d and S.A.L., unpublished observations). This manipulation
permitted comparison by using the Student's t test of the
mean natural logarithm (ln) of the length of each process
growing from RGCs in control and in aFGF-treated medium.
Fig. 4 c and d shows that significantly longer processes grew
in medium containing aFGF plus heparin compared to con-
trol. Thus, aFGF and heparin produced elongation as well as
initiation of neurites by RGCs.
Effect of aFGF plus Heparin on the Number of Glial Cells.
Under the present conditions, glial cells, represented by
Muller cells as well as by astrocytes, might be expected to be
glial fibrillary acid protein (GFAP)-positive (25-28). When
retinal cultures were incubated for 24 hr with aFGF (10
units/ml) and heparin (10 ,g/ml), there was only a slight
increase in the mean number of GFAP-positive cells. Con-
trol cultures contained 58 ± 9 glial cells, whereas aFGF plus
Table 1. Number of processes per RGC after 24 hr in control
medium or in medium containing aFGF plus heparin
Processes, no. per solitary RGC
Exp. aFGF, units/ml Control aFGF plus heparin
1 16 0.3 3.3
2 10 1.7 5.0
3 10 3.0 4.2
4 100 7.3 10.5
5 10 1.0 4.1
6 100 3.0 4.3
7 80 1.7 2.5
8 8 0.9 5.0
9 1 0.7 2.4
10 0.1 1.7 4.4
11 1 2.7 4.1
12 0.1 3.0 5.0
For each experiment 1 day after plating the retinal cultures, the
number of processes per solitary RGC was counted in a double-blind
manner for quadruplicate dishes in control medium and in medium
containing aFGF (0.1-100 units/ml) plus heparin (10 ,Lg/ml). In each
experiment '160 solitary RGCs were observed, and all processes
detectable at a magnification of x 500 under phase-contrast optics
were scored. The number of processes per RGC in medium contain-
ing aFGF plus heparin was significantly greater than in the controls
by the Sign test (P < 0.001).
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FIG. 4. Effect of aFGF (10 units/ml) plus heparin (10 ,ug/ml) on process length. The histograms represent the length of every neuronal
process on 40 consecutive RGCs scored for outgrowth under control conditions (a and c) and in the presence of aFGF plus heparin in a
representative experiment (b and d). For the controls, 137 processes were encountered on RGCs and analyzed; 223 processes were found in
the aFGF plus heparin-treated cultures. (a and b) Frequency of occurrence is plotted as a function of the linear length of the neurites. In a the
mean process length is 16.5 ,.m, and in b 22.7 tim. (c and d) Natural logarithm (in) of the process lengths is displayed for the data in a and b,
respectively. In c the mean In value is 2.58, and the SD is 0.48, and in d the mean In value is 2.80, and the SD is 0.50. The dotted lines represent
the Gaussian fit to the data by the computer using the listed parameters. The mean In value of the length of each process was significantly longer
on RGCs plated in aFGF plus heparin compared to control (P < 0.0005 by the Student's t test). Four additional experiments yielded similar
results.
heparin-treated cultures contained 68 ± 18 glial cells (mean
+ SEM, n = 10 cultures in each case). This difference is not
significant. Interestingly, the GFAP-positive cells in our
retinal cultures were nearly always in intimate contact with
clusters of retinal cells and only rarely with solitary RGCs.
The observations were consistent with the hypothesis that
the clustered retinal cells associated on the surface of the
glial cells.
DISCUSSION
Several purified polypeptide growth factors have been re-
ported to influence the growth of processes and survival of
neurons in the mammalian CNS. These substances presum-
ably interact with specific receptors on the cell surface that
in turn trigger a series of intracellular events that may
involve second messengers, ionic currents, and gene regu-
lation (4). These growth factors include nerve growth factor
(1, 29), neuroleukin (2), brain-derived growth factor (3), and
bFGF (12, 14). Our findings constitute evidence that another
peptide, a highly purified preparation of aFGF, has a pro-
found influence on the elaboration of processes by a CNS
neuron, the rat RGC. Interestingly, under the stated condi-
tions various concentrations of bFGF did not substantially
affect this system. In the present experiments 24 hr was
selected as the criterion period to compare our results on
process outgrowth induced by aFGF with studies involving
bFGF (ref. 12 and see below). Although aFGF did not
appear to influence the survival of RGCs after 24 hr in vitro,
it is of course possible that the enhanced process growth
represents the first manifestation of an increase in survival
that will only become apparent when the retinal cultures are
maintained for longer periods of time.
Our finding of an increase in neurite outgrowth by an
identified, mammalian central neuron is noteworthy for
three reasons. (i) By using fluorescent labels to identify the
cells, a specific class of central neurons has been studied. (ii)
Postnatal RGCs have been used, and thus process outgrowth
in these neurons represents, at least in part, regeneration of
axons in the mammalian CNS (18). (iii) Analysis of the
number and the length of processes growing in vitro (Table 1
and Fig. 4) reveals that the addition of aFGF plus heparin
resulted in an increase in both the initiation and elongation of
neurites.
In the presence of heparin (10 Ag/ml), half-maximal ef-
fects of aFGF on process outgrowth were observed at con-
centrations of <0.1 unit/ml (or 20 pg/ml), corresponding to
=1 pM. This finding indicates a potency of aFGF for process
outgrowth that may well exceed that of other polypeptide
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growth factors such as nerve growth factor or bFGF. For
example, Walicke et al. (12) reported that -1 pM bFGF was
necessary for the half-maximal effect of prolonged survival of
fetal rat hippocampal neurons in vitro but that 20 pM was
required for the half-maximal influence on neurite extension at
24 hr. Also of importance, doses of bFGF (25-50 pM) that
affected neurite outgrowth in embryonic cortical and hippo-
campal neurons (12, 14) had no substantial effect on RGC
neurite outgrowth under our conditions.
The question arises whether or not the increase in process
outgrowth by solitary RGCs observed in the present study
could be influenced by the glia (GFAP-positive cells) in the
cultures, expecially because aFGF leads to an increase in the
number of astrocytes in other culture systems (9). It seems
unlikely, however, that glial cells played a substantial role in
the growth of processes by solitary RGCs for two reasons.
(i) Comparing aFGF-treated cultures to control cultures, the
number of glial cells was not significantly greater at 24 hr,
the time chosen to study neurite outgrowth. Perhaps the
apparent difference between this finding and that of previous
studies (9) is due to the GFAP-positivity of Muller cells as
well as of astrocytes under the present conditions. (ii) In
general, solitary (in contradistinction to clustered) RGCs
were not in contact with GFAP-positive cells. Thus, any
effect of GFAP-positive cells on process regeneration by
solitary RGCs would have to be mediated by a soluble factor
that would have to be extremely potent to be able to act
through the relatively large volume of the culture medium (2
ml). Since aFGF is a neurite extension factor for PC12 cells,
a cloned line of neuroectodermal origin (11), there is a clear
precedent for the action of aFGF directly on a neural cell.
Nevertheless, it remains possible that aFGF acts on glial
cells that in turn produce another factor that enhances
process outgrowth by RGCs. Future studies that use the
direct application of aFGF from a micropipette immediately
adjacent to a solitary RGC while observing process growth
(as described for nerve growth factor in ref. 30) may resolve
the issue of direct aFGF effects on neurons.
The mechanism by which heparin potentiates aFGF is not
known, but the possibility that aFGF interacts with a hepa-
rin-like molecule in vivo warrants discussion. Matthew and
Patterson (31) have demonstrated that the monoclonal anti-
body INO binds to a laminin-heparan sulfate proteoglycan
binding site and inhibits neurite outgrowth from sympathetic
neurons. Interestingly, INO binds to the intact inner retina
of adult rodents in the same distribution as the binding of
Thy-1 monoclonal antibodies (V. Sehgal, L. Levin, and
S.A.L., unpublished observations). Since Thy-1 antibodies
had been shown to bind to the inner retina and RGCs (18, 32,
33), this finding is consistent with the notion that heparan
sulfate proteoglycan in the extracellular matrix is in close
apposition to RGCs. It is also known that aFGF has a
high-affinity binding site for heparin-like molecules (10).
Taken together, these results indicate that aFGF may bind in
the mammalian retina to extracellular matrix molecules
located in a position appropriate to influence process growth
by RGCs in vivo. In the future it should be possible to test
this hypothesis by determining if the regeneration of pro-
cesses by RGCs can be influenced by aFGF in the living
animal.
Interestingly, aFGF to a far greater degree than bFGF
promotes the outgrowth of processes by postnatal RGCs
while just the opposite appears to be true for fetal hippo-
campal neurons in culture (12, 15). These findings imply that
these homologous growth factors have differential effects on
disparate cell types in the mammalian CNS and indicate a
previously unrecognized degree of specificity to their ac-
tions. Remaining issues to be settled include (i) whether or
not aFGF and bFGF react with the same receptor (for a
review see ref. 17), (ii) the exact distribution of these
receptor(s) among different neuronal populations in the
CNS, and (iii) the physiological role of these factors.
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